Yvette Drew
BC Cancer Agency(CA)University of British Columbia(CA)Canadian Centre for Applied Research in Cancer Control(CA)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, DNA Repair Mechanisms, Cancer Genomics and Diagnostics
Most-Cited Works
- → Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)1,678 cited
- → Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors(2010)267 cited
- → Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2(2010)258 cited
- → Homologous recombination deficiency and ovarian cancer(2016)253 cited
- → First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors(2020)249 cited
- → A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline -Mutated Ovarian Carcinoma or Other Solid Tumors